Jeil Pharma Holdings Bilan de santé
Santé financière contrôle des critères 5/6
Jeil Pharma Holdings has a total shareholder equity of ₩436.3B and total debt of ₩149.4B, which brings its debt-to-equity ratio to 34.2%. Its total assets and total liabilities are ₩881.2B and ₩444.9B respectively.
Informations clés
34.2%
Ratio d'endettement
₩149.39b
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | ₩48.04b |
| Fonds propres | ₩436.29b |
| Total du passif | ₩444.87b |
| Total des actifs | ₩881.15b |
Mises à jour récentes de la santé financière
These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27
Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23
Recent updates
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Analyse de la situation financière
Passif à court terme: A002620's short term assets (₩387.7B) exceed its short term liabilities (₩376.7B).
Passif à long terme: A002620's short term assets (₩387.7B) exceed its long term liabilities (₩68.1B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: A002620's net debt to equity ratio (23.2%) is considered satisfactory.
Réduire la dette: A002620's debt to equity ratio has increased from 14.3% to 34.2% over the past 5 years.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: A002620 has sufficient cash runway for more than 3 years based on its current free cash flow.
Prévisions de trésorerie: A002620 has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 9% each year.